Oligo-fucoidan + fucoxanthin + L-carnitine

Oligo-fucoidan + fucoxanthin + L-carnitine has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Oct 21, 2026: “Adjunctive fucoidan, fucoxanthin, and l-carnitine mitigate albuminuria and preserve eGFR over a 12-week treatment period in diabetic kidney disease: A translational study and proof-of-concept randomized clinical trial”.

Intervention

1 paper studies it6 findingsUpdated

1 new paper in 30 daysSee all 1 papers on oligo-fucoidan + fucoxanthin + L-carnitine

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“FFL also significantly lowered baseline-adjusted LDL (GMR = 0.85; 95% CI: 0.76-0.95; p < 0.01)”
Adjunctive fucoidan, fucoxanthin, and l-carnitine mitigate albuminuria and preserve eGFR over a 12-week treatment period in diabetic kidney disease: A translational study and proof-of-concept randomized clinical trialPhytomedicine : international journal of phytotherapy and phytopharmacology2026doi:10.1016/j.phymed.2026.158870

None of its findings points the other way.

Mice and humans: a single group. Cells and worms or flies: nothing yet.
  • 1 lab in 1 country
  • Funders: Taipei Municipal Wan Fang Hospital and 1 more
  • Human trial1

Studies in people

1 study gave oligo-fucoidan + fucoxanthin + L-carnitine to people and measured what changed.

What changedDesignPeopleSource

down: Decreases urine albumin-to-creatinine ratioAdjusted 39.40% greater UACR reduction versus control; GMR 0.60 (95% CI 0.40–0.90); ITT: 32.18% greater reduction, GMR 0.67 (95% CI 0.48–0.93)

no change: Has no effect on estimated glomerular filtration ratePP adjusted GMR 1.01, p = 0.74; ITT adjusted GMR 1.01, p = 0.78

down: Decreases LDLGMR 0.85 (95% CI 0.76–0.95); maximum 24.28% reduction in patients with baseline dyslipidemia

Randomized trial12 weeks55 peopleDKD patients receiving SGLT2 inhibitors (100%) and ACEIs/ARBs (85.5%); per-protocol analysisPhytomedicine : international journal of phytotherapy and phytopharmacology, Oct 21, 2026

What did studies of oligo-fucoidan + fucoxanthin + L-carnitine find?

6

Studies of oligo-fucoidan + fucoxanthin + L-carnitine measured 6 outcomes, among them LDL, estimated glomerular filtration rate and urine albumin-to-creatinine ratio.

LDL

downin humans1

1 study
  1. Oligo-fucoidan + fucoxanthin + L-carnitine decreases LDL in humans (DKD patients receiving adjunctive FFL) (GMR 0.85 (95% CI 0.76–0.95); maximum 24.28% reduction in patients with baseline dyslipidemia).

    “FFL also significantly lowered baseline-adjusted LDL (GMR = 0.85; 95% CI: 0.76-0.95; p < 0.01)”

    Human trialDKD patients receiving adjunctive FFLstandardized marine formula12 weeks

    Adjunctive fucoidan, fucoxanthin, and l-carnitine mitigate albuminuria and preserve eGFR over a 12-week treatment period in diabetic kidney disease: A translational study and proof-of-concept randomized clinical trial

    Phytomedicine : international journal of phytotherapy and phytopharmacology

More on LDL

Estimated glomerular filtration rate

no changein humans1

1 study
  1. Oligo-fucoidan + fucoxanthin + L-carnitine showed no clear effect on estimated glomerular filtration rate in humans (DKD patients receiving adjunctive FFL; per-protocol analysis) (PP adjusted GMR 1.01, p = 0.74; ITT adjusted GMR 1.01, p = 0.78).

    “eGFR remained stable and preserved over 12 weeks (PP adjusted GMR = 1.01, p = 0.74; ITT adjusted GMR = 1.01, p = 0.78).”

    Human trialDKD patients receiving adjunctive FFL; per-protocol analysisstandardized marine formula12 weeksn = 55

    Adjunctive fucoidan, fucoxanthin, and l-carnitine mitigate albuminuria and preserve eGFR over a 12-week treatment period in diabetic kidney disease: A translational study and proof-of-concept randomized clinical trial

    Phytomedicine : international journal of phytotherapy and phytopharmacology

More on Estimated glomerular filtration rate

Urine albumin-to-creatinine ratio

downin humans1

1 study
  1. Oligo-fucoidan + fucoxanthin + L-carnitine decreases urine albumin-to-creatinine ratio in humans (Adjusted 39.40% greater UACR reduction versus control; GMR 0.60 (95% CI 0.40–0.90); ITT: 32.18% greater reduction, GMR 0.67 (95% CI 0.48–0.93)).

    “adjunctive FFL achieved a highly significant, adjusted 39.40% greater reduction in UACR compared to control”

    Human trialDKD patients receiving SGLT2 inhibitors (100%) and ACEIs/ARBs (85.5%); per-protocol analysisstandardized marine formula12 weeksn = 55

    Adjunctive fucoidan, fucoxanthin, and l-carnitine mitigate albuminuria and preserve eGFR over a 12-week treatment period in diabetic kidney disease: A translational study and proof-of-concept randomized clinical trial

    Phytomedicine : international journal of phytotherapy and phytopharmacology

More on Urine albumin-to-creatinine ratio

Inflammation

downin mice1

1 study
  1. Oligo-fucoidan + fucoxanthin + L-carnitine decreases inflammation in mice (diabetic CKD).

    “Preclinically, FFL significantly attenuated renal dysfunction, tubulointerstitial fibrosis, and inflammation.”

    Animalsdiabetic CKDstandardized marine formulakidney8 weeks

    Adjunctive fucoidan, fucoxanthin, and l-carnitine mitigate albuminuria and preserve eGFR over a 12-week treatment period in diabetic kidney disease: A translational study and proof-of-concept randomized clinical trial

    Phytomedicine : international journal of phytotherapy and phytopharmacology

More on Inflammation

Tubulointerstitial fibrosis

downin mice1

1 study
  1. Oligo-fucoidan + fucoxanthin + L-carnitine decreases tubulointerstitial fibrosis in mice (diabetic CKD).

    “Preclinically, FFL significantly attenuated renal dysfunction, tubulointerstitial fibrosis, and inflammation.”

    Animalsdiabetic CKDstandardized marine formulakidney8 weeks

    Adjunctive fucoidan, fucoxanthin, and l-carnitine mitigate albuminuria and preserve eGFR over a 12-week treatment period in diabetic kidney disease: A translational study and proof-of-concept randomized clinical trial

    Phytomedicine : international journal of phytotherapy and phytopharmacology

Renal dysfunction

downin mice1

1 study
  1. Oligo-fucoidan + fucoxanthin + L-carnitine decreases renal dysfunction in mice (diabetic CKD).

    “Preclinically, FFL significantly attenuated renal dysfunction, tubulointerstitial fibrosis, and inflammation.”

    Animalsdiabetic CKDstandardized marine formulakidney8 weeks

    Adjunctive fucoidan, fucoxanthin, and l-carnitine mitigate albuminuria and preserve eGFR over a 12-week treatment period in diabetic kidney disease: A translational study and proof-of-concept randomized clinical trial

    Phytomedicine : international journal of phytotherapy and phytopharmacology

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 01 paper in 12 months